IRVING, Texas, Nov. 2 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc., today announced that it has received a new international nomenclature for its Hydrapol(TM) powder. Hydrapol(TM), a proprietary product of Carrington, is the only commercially available raw material from Aloe vera L. with the International Nomenclature Cosmetic Ingredient (INCI) name of "Aloe Barbadensis Leaf Polysaccharides."
The INCI name assigned to Hydrapol(TM) by the Cosmetic, Toiletry and Fragrance Association (CTFA), a leading trade organization for the personal care market, was based on analyses and technical data, including composition of matter and toxicological data, submitted by Carrington.
"Traditionally processed Aloe vera L. raw materials are commonly listed as 'Aloe Barbadensis Leaf Juice' or 'Aloe Barbadensis Leaf Extract' in the ingredient declaration for cosmetics," stated Dr. Carlton Turner, president and CEO. "The new INCI name recognizes the real difference between products containing high levels of polymeric acetylated mannans (polysaccharides) such as our Hydrapol(TM) powder and other biologically inactive aloe raw materials."
Turner continued, "Our raw material contains greater than 50% polysaccharides by weight with an average molecular weight greater than 1.4 million Daltons. One of our polysaccharides, Acemannan Hydrogel(TM), stimulates the immune system and is a known compound used in wound healing. In fact, a published report by Dr. James Talmadge in the December 2004 issue of International Immunopharmacology again confirms the strong immunomodulatory properties of Acemannan. Hydrapol(TM) also stimulates macrophage activation and results in significant cytokine release. Only products containing our Hydrapol(TM) powder will be able to refer to their ingredient as 'Aloe Barbadensis Leaf Polysaccharides.'"
The new nomenclature for Hydrapol(TM) powder will be published in the CTFA's International Cosmetic Ingredient Dictionary and Handbook. The ICI Dictionary is recognized by the United States Food and Drug Administration as a reference manual for the proper identification of ingredients used in products classified as cosmetics.
About Hydrapol(TM) Powder
Hydrapol(TM) is a "product by process" and protected by many patents, including U.S. Patent Numbers 4,917,890 and 5,902,796. It is the only raw material from Aloe vera L. developed specifically for the personal care industry that contains quantifiable amounts of aloe polysaccharides. Studies with Hydrapol(TM) powder have shown anti-inflammatory capabilities and retention of moisture on the skin due to its film-forming capabilities. Hydrapol(TM) powder can be used in a wide range of cosmetic and personal care products for the face, body, and hair. A chromatographic profile comparison between other commercial products from aloe and Hydrapol(TM) is available by calling Ms. Pamela Schonbeck or Ms. Maria Eaton at 972-518-1300.
About Carrington
Carrington Laboratories, Inc., is an ISO 9001-certified, research-based biopharmaceutical and consumer products company currently utilizing naturally- occurring polymeric carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products under the AloeCeuticals(R) brand and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. The Company's DelSite Biotechnologies subsidiary is developing its propriety GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products are honored with the internationally coveted CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com .
Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-Q filed August 15, 2005.
Carrington Laboratories, Inc.CONTACT: Pamela Schonbeck or Maria Mitchell, both of CarringtonLaboratories, Inc., +1-972-518-1300
Web site: http://www.carringtonlabs.com/
